BioAtla to Participate in the Citizens JMP Life Sciences Conference
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors [Yahoo! Finance]
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
BioAtla: A Buried ADC Concern Gets Some New Life In 2024 [Seeking Alpha]